Higher costs of revenue hurt the genomic sequencing company in the fourth quarter.
This genomic sequencing leader appears to be suffering from multiple revenue headwinds -- at least in the near term.
Here's what it will take for this genomic sequencing company to succeed in 2016.
A slower than hoped for launch of the company's new Sequel System is pressuring shares on Monday.
The introduction of a new and cheaper gene sequencing model could give this company an edge.
A double-digit jump on no news.
Investors continue to grow bullish on the company's near term prospects, sending shares to a fresh 52-week high.
The launch of a new sequencing platform gives investors a strong reason to cheer.
Strong growth in tests combined with an increase in reimbursement.
Nothing special here, but nothing bad, either. Look forward to 2016.